Definitive Contract 75A50122C00079

Award Date 1/3/23
Potential Completion Date 6/30/27
Potential Value $16M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Fountain Hill, PA 18015, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Orasure Technologies Inc. to develop improvements to the OraQuick Ebola Rapid Antigen Test. The $15,504,106.00 cost-plus-fixed-fee contract aims to increase the test's sensitivity and shelf life, develop sustainable reagents, transition manufacturing to an automated line, and purchase two lots of approximately 10,000 improved tests. This is a sole-source award, as Orasure's OraQuick product is the only FDA-cleared rapid antigen test for Ebola that can be used on oral fluids from cadavers. The contract also references Orasure's existing indefinite delivery vehicle (IDV) contracts with the Defense Logistics Agency and GSA Federal Supply Schedule, which allow federal agencies to efficiently procure their diagnostic tests and supplies. No set-aside designation was used for this award.

Generated 3/14/25, 10:07 AM